Pasithea Therapeutics (KTTA) Competitors $1.30 -0.05 (-3.70%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.30 0.00 (0.00%) As of 02/21/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends KTTA vs. PBM, RNAZ, APLM, OBSV, ADXN, NEUP, ENSC, HOTH, EVOK, and RDHLShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Psyence Biomedical (PBM), TransCode Therapeutics (RNAZ), Apollomics (APLM), ObsEva (OBSV), Addex Therapeutics (ADXN), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Ensysce Biosciences (ENSC), Hoth Therapeutics (HOTH), Evoke Pharma (EVOK), and RedHill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Psyence Biomedical TransCode Therapeutics Apollomics ObsEva Addex Therapeutics Neuphoria Therapeutics Inc. - Common Stock Ensysce Biosciences Hoth Therapeutics Evoke Pharma RedHill Biopharma Pasithea Therapeutics (NASDAQ:KTTA) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership. Which has more volatility & risk, KTTA or PBM? Pasithea Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.48, meaning that its share price is 148% less volatile than the S&P 500. Does the media refer more to KTTA or PBM? In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Psyence Biomedical'saverage media sentiment score. Company Overall Sentiment Pasithea Therapeutics Neutral Psyence Biomedical Neutral Which has higher earnings & valuation, KTTA or PBM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/A-$15.96MN/AN/APsyence BiomedicalN/AN/A-$51.16MN/AN/A Does the MarketBeat Community believe in KTTA or PBM? Pasithea Therapeutics received 2 more outperform votes than Psyence Biomedical when rated by MarketBeat users. CompanyUnderperformOutperformPasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Psyence BiomedicalN/AN/A Is KTTA or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -81.57% -74.31% Psyence Biomedical N/A N/A N/A Do institutionals & insiders believe in KTTA or PBM? 23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryPasithea Therapeutics beats Psyence Biomedical on 4 of the 7 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / SalesN/A313.46457.9780.74Price / CashN/A67.8344.0437.47Price / Book0.066.747.634.64Net Income-$15.96M$138.11M$3.18B$245.69M7 Day Performance-10.34%-2.02%-1.82%-2.63%1 Month Performance-48.62%-1.54%0.22%-2.37%1 Year Performance-82.67%-3.14%17.49%13.65% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics0.7686 of 5 stars$1.30-3.7%N/A-82.7%$1.65MN/A0.003PBMPsyence BiomedicalN/A$1.26-7.7%N/A-97.0%$8.32MN/A0.00N/APositive NewsRNAZTransCode Therapeutics2.1775 of 5 stars$11.80+19.7%$20.00+69.5%-98.9%$8.26MN/A0.009APLMApollomics2.438 of 5 stars$7.46-10.7%$200.00+2,581.0%-89.7%$8.13M$1.22M0.0045Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastGap UpADXNAddex Therapeutics2.5252 of 5 stars$7.35-5.0%$30.00+308.2%-25.0%$7.79M$1.83M-21.6230NEUPNeuphoria Therapeutics Inc. - Common Stock2.2867 of 5 stars$4.71+0.4%$21.00+345.9%N/A$7.68M$10,000.000.00N/AEarnings ReportENSCEnsysce Biosciences0.224 of 5 stars$5.80-5.8%N/A-61.3%$7.60M$2.23M-0.2110HOTHHoth Therapeutics2.8251 of 5 stars$1.08-6.9%$4.00+270.4%-21.5%$7.45MN/A-0.824Gap DownEVOKEvoke PharmaN/A$4.84+0.6%N/A-40.8%$7.19M$8.62M-0.444Gap DownRDHLRedHill Biopharma0.5846 of 5 stars$5.59+1.6%N/A-98.6%$7.16M$6.53M0.00210Positive News Related Companies and Tools Related Companies Psyence Biomedical Alternatives TransCode Therapeutics Alternatives Apollomics Alternatives ObsEva Alternatives Addex Therapeutics Alternatives Neuphoria Therapeutics Inc. - Common Stock Alternatives Ensysce Biosciences Alternatives Hoth Therapeutics Alternatives Evoke Pharma Alternatives RedHill Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KTTA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
